Received: 26 March 2020
Accepted: 18 June 2020
First Online: 3 July 2020
Ethics approval and consent to participate
: The analysis was approved by the independent ethics committee of the University Hospital Essen (19–9004-BO) and all patients gave written consent to general analysis of their personal and clinical data.
: Not applicable.
: AS received travel fees from Teva, honoraria for participation on an advisory board of Novartis. SW reports personal fees from Allergan, personal fees from Tea, personal fees from Novartis, outside the submitted work. MG received honoraria from Novartis, UCB, Teva, Bayer, Novocure, Medac, Merck, Kyowa Kirin, has a consulting or advisory role to declare for Roche, Novartis, AbbVie, Novocure, and Daiichi Synkyo, and received travel fees from Novocure and Medac. SN reports grants from Novartis, personal fees from Novartis, personal fees from Teva, outside the submitted work. DH has received scientific support and/or honoraria from Biogen, Novartis, Lilly, Sanofi-Aventis, Teva, Allergan, Hormosan. OM, MN and CK declare that they have no competing interests.